[COMPLETED] The Irish Wolfhound Osteosarcoma Treatment Study: Alendronate (Fosamax) for Palliative Treatment of Irish Wolfhound Osteosarcoma
Approximately 25% of IWs die from osteosarcoma. This cancer is aggressive and painful and life expectancy without treatment varies from a few weeks to 3-6 months. Therapy is often very difficult for an IW.
In 2000 after an article was published documenting the success of Fosamax (alendronate) as use for palliative therapy for osteosarcoma in two dogs, the Irish Wolfhound Foundation sponsored a study with Dr. William Dernell, veterinary oncologist from Colorado State University. Dr. Dernell is reviewing the data from the thirty dogs who participated, and will submit a paper outlining his conclusions for publication in the veterinary literature within the year.
Additional Study Details
| Study Date(s): | 2001-11-01 |
|---|---|
| Study Status: | Completed |
| Enrollment Status: | CLOSED to new enrollment |
| Lead Researcher(s): | William Dernell DVM, MS, Diplomate ACVS |